Boyds is delighted to announce the appointment of Matt O’Connor who joins the company as Senior Manager, Regulatory Affairs.
Matt joins Boyds following more than five years at DLRC, where he gained broad experience across the regulatory lifecycle, supporting regulatory procedures in varied therapeutic areas. He is also a member of The Organisation for Professionals in Regulatory Affairs (TOPRA).
Matt has a PhD from the University of Nottingham, where he researched the molecular misfolding of prion diseases in small ruminants. Prior to working in regulatory affairs, Matt was a post-doctoral…
Seasoned executive joins PrecisionLife to drive commercial strategy for new first-in-class precision medicine tests to predict and prevent complex, chronic diseasesOXFORD, UK – 8 January 2025 – PrecisionLife, a leading precision medicine company focused on complex chronic diseases, announces the appointment of Bill Keating as Chief Commercial Officer, Diagnostics and Healthcare to lead the commercialization of precision medicine applications from its range of innovative new Mechanostic® tests in complex chronic diseases. With over 20 years of experience in senior Corporate and Business…
Read One Nucleus' eNews January issue here
With Tony Jones, One Nucleus' CEO, guiding you on your journey to success in 2025, by signposting you to:
✅ Will Your 2025 Get Off to a Flying Start?✅ Money: Investment, Partnering & Business Development✅ People✅ Technology✅ Reflections on Genesis 2024✅ One Nucleus Annual Awards
Cambridge, UK, 25 November 2024: Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Lee Patterson as its new CEO, effective from 2nd December 2024. An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets. He succeeds Dr Andrew Southan, who has decided to step down as CEO after five years in the post.
A renowned leader in the…
Pioneer Group has today announced a collaboration agreement with Thermo Fisher Scientific to support biotech founders on their journey towards commercialising intellectual property in the healthcare and sustainability sectors.
Through the collaboration, biotech startups based at Pioneer sites across the UK and Ireland, including its new landmark life sciences location at Victoria House in London in partnership with Oxford Properties, will receive access to training, events, technical support, bespoke equipment, and consumables from Thermo Fisher. In addition, companies that graduate from…
We are delighted to invite our network to attend our upcoming roundtable breakfast in collaboration with Cambridgeshire Chambers of Commerce.
Have a look at our exclusive invitation here and submit your registrations! Limited spaces available...
AMSBIO has implemented a program of investment to support the students at Penn State Lehigh Valley, part of Pennsylvania State University, in their transformative Course-based Undergraduate Research Experience (CURE) program.
The CURE program, led by Dr. Jacqueline McLaughlin, allows students to dive into real-world research projects that tackle critical challenges in health and medicine. This semester’s focus is on exploring the endothelial glycocalyx—a sugar-rich layer vital for cardiovascular health.
In this project, students analysed how various basement…
The European Partnership for Personalised Medicine introduces two exciting opportunities for start-ups, researchers, and early-stage teams working on cutting-edge solutions in personalized medicine. These programmes aim to accelerate the development, validation, and market readiness of transformative innovations that enhance patient care.
Fast Track Validation Programme
Designed to address a critical bottleneck in personalized medicine development, this programme supports validation studies to elevate projects to higher technological and market readiness levels.
Who Can Apply? …
Read eNews for December here. Featuring:
✅ Tony Jones, CEO, One Nucleus - Tis the Season to be Jolly!✅ Key Dates for Your 2025 Diary by Alicia Gailliez, Business Development Manager, One Nucleus✅ Reflections on Genesis 2024✅ One Nucleus Engagement in JPM Week 2025 by Tony Jones, One Nucleus✅ Memes Meet Microbes: Spreading Awareness About Antimicrobial Resistance by CSIRO✅ A Decade of Innovation, a Decade to Come - China’s Biopharmaceutical Innovation by Clarivate
Inaphaea BioLabs, the translational contract research organisation based at MediCity Nottingham, has announced the promotion of Melissa Barr to Head of Scientific Operations.
Melissa joined Inaphaea in 2023 as Lead Scientist. Since then, she has played an instrumental role in delivering preclinical drug discovery projects across oncology and women’s health, as well as leading a team of scientists on-site.
Spun out from ValiRx PLC, Inaphaea offers cell-based assays specialising in oncology. Its aim is to improve the translation of early drug discovery projects towards the clinic.
Commenting…